BGPT: Best Evidence: Pharmacogenomics and Ancestry

Explore by Goal

Long Analysis Plan Copied

Evidence Gap: No TB Treatment Data Supplied

The supplied records contain no tuberculosis-treatment pharmacogenomics — no NAT2, isoniazid, rifampicin, ethambutol, or hepatotoxicity/ADR data. The title's core claims cannot be battle-tested; any ancestry-based ADR-risk conclusion for TB would be fabricated. What the records do support is limited to general PGx infrastructure and ancestry-varying allele frequencies.

The Pharmacogenomics of Membrane Transporters Project reports ancestry-stratified frequencies for functional transporter variants (e.g., SLC22A1 M420del: 18.5% European Americans vs 0% Asians; SLC22A1 R61C: 7.2% European Americans, 0% African Americans/Asians), demonstrating why ancestry matters for drug-disposition risk — but for non-TB drugs and transporters, not TB anti-mycobacterials .

Verdict: The evidence package fails to substantiate the stated claim. To evaluate it, BGPT needs TB-specific sources: NAT2 acetylator-genotype and isoniazid hepatotoxicity cohorts, TPMT/UGT data for rifampicin, and ancestry-stratified ADR incidence with sample sizes.

Feedback:

Updated: October 26, 2026

Top Data Sources Export MCP

1. This study presents the design specifications for an integrated electronic pharmacogenomics assistant (ePGA) aimed at providing personalized drug recommendations based on genotype-phenotype associations to enhance clinical decision-making in pharmacogenomics. [2014]

7QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

2. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. This study provides practical considerations for selecting a clinical laboratory for pharmacogenomic testing, emphasizing the importance of pharmacogene and variant selection, logistics, result reporting, and cost in the implementation of pharmacogenomics in patient care. [2017]

7QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

4. The Pharmacogenomics of Membrane Transporters Project (PMT) investigates the genetic variations in membrane transporters and their implications for drug disposition and response, highlighting significant findings in pharmacogenomics and transporter biology. [2009]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. This study evaluates the prevalence of drug use among nursing home residents in Denmark for medications with pharmacogenomics-based dosing guidelines, highlighting the potential for preemptive pharmacogenomic testing to improve medication safety and efficacy. [2020]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

Ancestry-variant frequency data like the PMT project's exists for transporters, but the requested TB claim lacks any supporting record — illustrating how a plausible-sounding title can carry zero verifiable evidence content.

Keep Exploring

What is the magnitude and ancestry distribution of NAT2 slow-acetylator genotype effects on isoniazid-induced liver injury across high-TB-burden countries?

How do CPIC and DPWG guidelines differ in ancestry-adjusted dosing recommendations for first-line anti-TB drugs?

Hypothesis Graveyard

The premise title accurately reflects the supplied evidence: falsified — none of the eight records address TB treatment, NAT2, or anti-TB drug ADRs.

Potential Experiments

Cross-reference NAT2 genotype frequencies (1000 Genomes by super-population) against published isoniazid-induced liver injury rates per country to test whether ancestry-stratified acetylator status predicts reported hepatotoxicity incidence.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data is rich in published PGx-TB literature (NAT2/isoniazid associations), which risks tempting me to fill the missing evidence from memory rather than flagging its absence; I resisted this.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Long Analysis Plan Copied

Evidence Gap: No TB Treatment Data Supplied

Top Data Sources Export MCP

1. This study presents the design specifications for an integrated electronic pharmacogenomics assistant (ePGA) aimed at providing personalized drug recommendations based on genotype-phenotype associations to enhance clinical decision-making in pharmacogenomics. [2014]

2. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

3. This study provides practical considerations for selecting a clinical laboratory for pharmacogenomic testing, emphasizing the importance of pharmacogene and variant selection, logistics, result reporting, and cost in the implementation of pharmacogenomics in patient care. [2017]

4. The Pharmacogenomics of Membrane Transporters Project (PMT) investigates the genetic variations in membrane transporters and their implications for drug disposition and response, highlighting significant findings in pharmacogenomics and transporter biology. [2009]

5. This study evaluates the prevalence of drug use among nursing home residents in Denmark for medications with pharmacogenomics-based dosing guidelines, highlighting the potential for preemptive pharmacogenomic testing to improve medication safety and efficacy. [2020]

6. This study explores the role of pharmacogenomics in optimizing drug therapy for diabetes, HIV infection, and pain management by identifying genetic factors that influence drug response and efficacy. [2013]

8. This report discusses the integration of pharmacogenomics into clinical practice, highlighting the challenges posed by direct-to-consumer DNA testing and the need for education in personalized medicine. [2009]

10. This review discusses the influence of genetic variation on drug response in cancer treatment, emphasizing the importance of pharmacogenomics in personalizing therapy to improve efficacy and safety. [2012]

11. This study describes the implementation and assessment of an elective pharmacogenomics course for pharmacy students, highlighting its effectiveness in enhancing students' understanding and application of pharmacogenomic data in clinical decision-making. [2011]

12. This scoping review examines the evolution and geographical distribution of pharmacogenomics tools, highlighting the predominance of high-income countries in their development and the significant gaps in low-and middle-income countries (LMICs). [2025]

Ask a Follow-Up

Key Insight

Ancestry-variant frequency data like the PMT project's exists for transporters, but the requested TB claim lacks any supporting record — illustrating how a plausible-sounding title can carry zero verifiable evidence content.

Keep Exploring

What is the magnitude and ancestry distribution of NAT2 slow-acetylator genotype effects on isoniazid-induced liver injury across high-TB-burden countries?

How do CPIC and DPWG guidelines differ in ancestry-adjusted dosing recommendations for first-line anti-TB drugs?

Hypothesis Graveyard

The premise title accurately reflects the supplied evidence: falsified — none of the eight records address TB treatment, NAT2, or anti-TB drug ADRs.

Potential Experiments

Cross-reference NAT2 genotype frequencies (1000 Genomes by super-population) against published isoniazid-induced liver injury rates per country to test whether ancestry-stratified acetylator status predicts reported hepatotoxicity incidence.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data is rich in published PGx-TB literature (NAT2/isoniazid associations), which risks tempting me to fill the missing evidence from memory rather than flagging its absence; I resisted this.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Long Analysis Plan Copied

Evidence Gap: No TB Treatment Data Supplied

Top Data Sources ExportMCP

1. This study presents the design specifications for an integrated electronic pharmacogenomics assistant (ePGA) aimed at providing personalized drug recommendations based on genotype-phenotype associations to enhance clinical decision-making in pharmacogenomics. [2014]

2. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

3. This study provides practical considerations for selecting a clinical laboratory for pharmacogenomic testing, emphasizing the importance of pharmacogene and variant selection, logistics, result reporting, and cost in the implementation of pharmacogenomics in patient care. [2017]

4. The Pharmacogenomics of Membrane Transporters Project (PMT) investigates the genetic variations in membrane transporters and their implications for drug disposition and response, highlighting significant findings in pharmacogenomics and transporter biology. [2009]

5. This study evaluates the prevalence of drug use among nursing home residents in Denmark for medications with pharmacogenomics-based dosing guidelines, highlighting the potential for preemptive pharmacogenomic testing to improve medication safety and efficacy. [2020]

6. This study explores the role of pharmacogenomics in optimizing drug therapy for diabetes, HIV infection, and pain management by identifying genetic factors that influence drug response and efficacy. [2013]

8. This report discusses the integration of pharmacogenomics into clinical practice, highlighting the challenges posed by direct-to-consumer DNA testing and the need for education in personalized medicine. [2009]

10. This review discusses the influence of genetic variation on drug response in cancer treatment, emphasizing the importance of pharmacogenomics in personalizing therapy to improve efficacy and safety. [2012]

11. This study describes the implementation and assessment of an elective pharmacogenomics course for pharmacy students, highlighting its effectiveness in enhancing students' understanding and application of pharmacogenomic data in clinical decision-making. [2011]

12. This scoping review examines the evolution and geographical distribution of pharmacogenomics tools, highlighting the predominance of high-income countries in their development and the significant gaps in low-and middle-income countries (LMICs). [2025]

Ask a Follow-Up

Key Insight

Ancestry-variant frequency data like the PMT project's exists for transporters, but the requested TB claim lacks any supporting record — illustrating how a plausible-sounding title can carry zero verifiable evidence content.

Keep Exploring

What is the magnitude and ancestry distribution of NAT2 slow-acetylator genotype effects on isoniazid-induced liver injury across high-TB-burden countries?

How do CPIC and DPWG guidelines differ in ancestry-adjusted dosing recommendations for first-line anti-TB drugs?

Hypothesis Graveyard

The premise title accurately reflects the supplied evidence: falsified — none of the eight records address TB treatment, NAT2, or anti-TB drug ADRs.

Potential Experiments

Cross-reference NAT2 genotype frequencies (1000 Genomes by super-population) against published isoniazid-induced liver injury rates per country to test whether ancestry-stratified acetylator status predicts reported hepatotoxicity incidence.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data is rich in published PGx-TB literature (NAT2/isoniazid associations), which risks tempting me to fill the missing evidence from memory rather than flagging its absence; I resisted this.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP